1. Show article details.

    Johnson & Johnson to Participate in the 2015 Wells Fargo 10th Annual Healthcare Conference

    PR Newswire – 5:28 PM ET 08/27/2015

    NEW BRUNSWICK, N.J., Aug. 27, 2015  Johnson & Johnson (JNJ) will participate in the 2015 Wells Fargo 10th Annual Healthcare Conference on Thursday, Sept. 10, at The Hyatt Regency Boston.

  2. Show article details.

    J&J Sells Splenda Sweetener

    DJ Business News – 3:45 PM ET 08/25/2015

    The artificial sweetener brand Splenda is changing hands, as Heartland Food Products Group agreed to buy it from a subsidiary of Johnson& Johnson. Heartland said private-equity firm Centerbridge Partners LP assisted in sealing the deal and would become a shareholder in Heartland after the acquisition is completed. Splenda sweetener products contain sucralose, a no-calorie sweetener.

  3. Show article details.

    Heartland Food Products to Buy Splenda From J&J Unit

    DJ Business News – 3:27 PM ET 08/25/2015

    Heartland Food Products Group said Tuesday it reached an agreement to acquire the artificial sweetener brand Splenda from a subsidiary of Johnson& Johnson. Heartland said private-equity firm Centerbridge Partners LP assisted in closing the deal and would become a shareholder in Heartland after the acquisition is completed. Heartland is based outside Indianapolis and produces sucralose, stevia and other sweeteners.

  4. Show article details.

    BRIEF-Hutchison China Medi says Janssen terminates R&D alliance for HMPL-507 project

    Reuters – 7:23 AM ET 08/19/2015

    Hutchison China Medi. * Termination of research & development alliance agreement with janssen relating to HMPL-507 project. * Janssen, at its sole discretion, has decided not to proceed with either hmpl-507 or any of backup compounds developed under agreement. * Hmp and janssen will continue to work together on projects in other contexts.

  5. Show article details.

    UK watchdog requires Reckitt to license K-Y brand for 8 yrs

    Reuters – 9:19 AM ET 08/12/2015

    Britain's competition watchdog on Wednesday said consumer goods maker Reckitt Benckiser must license the K-Y brand in Britain to a third party for eight years, to assuage concerns about competition arising from its proposed purchase of the brand from Johnson & Johnson.

  6. Show article details.

    Reckitt Benckiser Gets U.K. Approval to Buy K-Y Lubricants

    DJ Business News – 7:15 AM ET 08/12/2015

    Reckitt Benckiser Group PLC (RBGPF) has received regulatory clearance from U.K. authorities to buy the K-Y brand of intimate lubricants from Johnson& Johnson, but will be forced to license out the brand for several years. The U.K. consumer-goods company, which already owns condom brand Durex, agreed to buy K-Y last year. The acquisition ran into a roadblock in December when the U.K.' s Competition and Markets Authority said the deal could result in a "substantial lessening of competition" and...

  7. Show article details.

    Reckitt Benckiser Gets U.K. Regulatory Approval to Buy K-Y Lubricants

    DJ Business News – 4:31 AM ET 08/12/2015

    Reckitt Benckiser Group PLC (RBGPF) has received regulatory clearance from U.K. authorities to buy the K-Y brand of intimate lubricants from Johnson& Johnson, but will be forced to license out the brand for several years. The U.K. consumer-goods company, which already owns condom brand Durex, agreed to buy K-Y last year. The acquisition ran into a roadblock in December when the U.K.' s Competition and Markets Authority said the deal could result in a "substantial lessening of competition" and...

  8. Show article details.

    Mallinckrodt to Buy Immunotherapy Firm Therakos

    DJ Business News – 7:35 AM ET 08/10/2015

    Mallinckrodt PLC (MNK) on Monday said it would buy privately-held immunotherapy company Therakos Inc. for about $1.325 billion, the latest deal for the acquisitive pharmaceutical company. Mallinckrodt (MNK), which was spun off from Covidien PLC in 2013, said the purchase is a move to grow its hospital business within its specialty brands portfolio. The company, like many others in the space, has sought to grow through acquisitions.

  9. Show article details.

    GLOBAL MARKETS WEEKAHEAD-Can stocks hold up as the U.S. dollar rises and commodities fall ?

    Reuters – 9:10 PM ET 08/09/2015

    The question investors are pondering during the remainder of the northern hemisphere summer is whether major stock markets can sustain this year's relatively high valuations given the slump in commodity prices, a firm U.S. dollar, and the likelihood of a Federal Reserve interest rate rise in September.

  10. Show article details.

    J&J gets partial win against Covidien in surgical patent case

    Reuters – 11:32 AM ET 08/07/2015

    Johnson & Johnson (JNJ) subsidiary Ethicon Endo-Surgery Inc will get a second chance to hold rival surgical instrument maker Covidien Plc liable for allegedly infringing two patents on a specialized ultrasonic scalpel that cuts and seals blood vessels.

  11. Show article details.

    Johnson & Johnson gets partial win in patent appeal against Covidien

    Reuters – 10:30 AM ET 08/07/2015

    Johnson & Johnson (JNJ) subsidiary Ethicon Endo-Surgery Inc will get a second chance to hold rival surgical instrument maker Covidien Plc liable for allegedly infringing two patents on a specialized ultrasonic device that cuts and seals blood vessels.

  12. Show article details.

    PRESS DIGEST- New York Times business news - Aug 7

    Reuters – 1:26 AM ET 08/07/2015

    The following are the top stories on the New York Times business pages. * The American fertilizer maker CF Industries Holdings Inc (CF) said on Thursday that it had agreed to acquire several European and North American operations and a global distribution business from OCI NV of the Netherlands for $8 billion, including debt.

  13. Show article details.

    INSIGHT-Pfizer, Bristol revive cancer drugs that rev up immune system

    Reuters – 1:00 AM ET 08/07/2015

    Some of the most heralded new cancer drugs fight the disease by removing brakes on the immune system. Pfizer Inc (PFE), which is lagging rivals in the lucrative field of cancer immunotherapies, has been the first to report early data of an "accelerator" treatment that targets a protein called 4-1BB.

  14. Show article details.

    IBM Deal Will Add to Its Watson Health Service

    DJ Business News – 10:15 AM ET 08/06/2015

    International Business Machines Corp. (IBM) added to its Watson Health platform Thursday by agreeing to buy Merge Healthcare Inc. (MRGE) in a cash deal that gives the medical image company an equity value of about $700 million. The offer of $7.13 a share is a 32% premium to Merge's closing price of $5.41 a share on Wednesday. Based on Merge's 98.9 million shares outstanding as of July 28, the deal is valued at $705 million.

  15. Show article details.

    CVS strips Viagra, other top drugs, from insurance coverage

    Reuters – 5:37 PM ET 08/05/2015

    CVS Health Corp (CVS), which operates the nation's second-biggest pharmacy benefit manager, said that next year it will exclude an additional 31 prescription medicines from insurance coverage, including Viagra and widely used treatments for diabetes and multiple sclerosis.

  16. Show article details.

    Depomed to File Injunction Against Pursuer Horizon

    DJ Business News – 1:05 PM ET 08/03/2015

    Depomed Inc. (DEPO) said Monday that it would attempt to block Horizon Pharma PLC (HZNP) from using confidential data, a week after the company rejected Horizon's roughly $2 billion hostile takeover bid. In a news release, Depomed (DEPO) said Horizon's bid is "predicated on the improper and unlawful use of highly confidential and proprietary information" relating to Depomed's (DEPO) leading pain drug. The company plans to file an injunction to prevent Horizon from continuing its alleged use of Depomed's...

  17. Show article details.

    After Merck success, work goes on with other Ebola vaccines

    Reuters – 11:29 AM ET 07/31/2015

    Scientists and drug companies will continue to research the potential of alternative Ebola vaccines, despite a shot from Merck and NewLink Genetics (NLNK) proving 100 percent effective in a trial in Guinea. Experts said on Friday different kinds of vaccines were needed that might be better suited for different population groups.

  18. Show article details.

    Merck Earnings Hurt by Arthritis Drug Knockoffs

    DJ Business News – 8:05 AM ET 07/28/2015

    Low-cost knockoffs of the arthritis treatment Remicade in Europe hurt Merck& Co.' s second-quarter sales and earnings, a harbinger of the pressure facing sellers of other costly biotechnology drugs in the coming years. Merck, which handles Remicade marketing in Europe, said the company's sales of the drug declined 25% to $455 million for the quarter, as European doctors prescribed copycat versions that cost up to 45% less than the branded drug. Companies including Hospira Inc....

  19. Show article details.

    Horizon Boosts Depomed Bid to About $2 Billion

    DJ Business News – 1:05 PM ET 07/21/2015

    Horizon Pharma PLC (HZNP) ramped up its pursuit of Depomed Inc. (DEPO), increasing its bid for the company to about $2 billion in a proposed all-stock deal. Still, shares of Depomed (DEPO) traded above the revised offer price Tuesday, indicating investors may not think the bid will be enough to secure a deal. Shares of Depomed (DEPO) were up 2.3% to $33.50 midday, while Horizon shares fell 0.3% to $37.20.

  20. Chevron leads Dow gainers, up 0.6% in early trade

    MarketWatch – 9:36 AM ET 07/21/2015
Page:

Today's and Upcoming Events

  • Oct
    13

    JNJ to announce Q3 earnings Before Market (Unconfirmed)

Past Events (last 90 days)

  • Aug
    21

    JNJ ex-Dividend for $0.75 on 8/21/2015

    • Announce Date: 7/20/2015
    • Record Date: 8/25/2015
    • Pay Date: 9/8/2015
Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.